ASH 2021 Conference Coverage on VuMedi

 

ASH 2021 Conference Coverage on VuMedi
T

ASH 2021 on a Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular MRD and Early Relapse in AML

By ASH 2021 Conference Coverage on VuMedi FEATURING Tiong Ing Soo
By ASH 2021 Conference Coverage on VuMedi FEATURING Tiong Ing Soo
15 views
January 11, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

07:44
Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal
Leukemia
06:56

Acalabrutinib vs. Rituximab + Idelalisib/Bendamustine in R/R CLL: 3-…

ASH 2021 Conference Coverage on VuMedi

P. Ghia

124 views
08:45

ASH 2021 Updated Results From the Phase 3 QUAZAR AML-001 Trial: Long…

ASH 2021 Conference Coverage on VuMedi

A. Wei

710 views
10:00

ASH 2021 Updates on Asciminib vs. Investigator-Selected TKI in Newly…

ASH 2021 Conference Coverage on VuMedi

J. Cortés

114 views
12:00

ASH 2021 Highlights on ALLG Phase 2 INTERVENE Study: Investigating N…

ASH 2021 Conference Coverage on VuMedi

C. Chua

19 views
08:50

ASH 2021 Results From the SEQUOIA Study: Zanubrutinib vs. Bendamusti…

ASH 2021 Conference Coverage on VuMedi

C. Tam

113 views
07:00

ASH 2021 on a Study of Venetoclax and Low Dose Ara-C (VALDAC) to Tar…

ASH 2021 Conference Coverage on VuMedi

T. Ing Soo

15 views
12:07

ASH 2021 Long Term Follow-Up and Combined Phase 2 Results of Eprenet…

ASH 2021 Conference Coverage on VuMedi

D. Sallman

76 views
11:06

ASH 2021 MRD Assessment in CLL

ASH 2021 Conference Coverage on VuMedi

P. Ghia

385 views
05:49

ASH 2021 Update on the Safety & Efficacy of Menin Inhibition in MLL-…

ASH 2021 Conference Coverage on VuMedi

E. Stein

130 views
08:38

ASH 2021 Clinical Predictors of Outcomes in Adult Acute Leukemias an…

ASH 2021 Conference Coverage on VuMedi

P. Desai

277 views
09:55

ASH 2021: Comparing Outcomes Between CPX-351 and HMA+Ven As 1L Thera…

ASH 2021 Conference Coverage on VuMedi

P. Desai

102 views
12:29

ASH 2021 on Older Patients With AML: So I Am in Remission - Now What?

ASH 2021 Conference Coverage on VuMedi

P. Desai

518 views
05:46

ASH 2021: Outcomes of Patients Treated With CPX-351 as 1L Therapy fo…

ASH 2021 Conference Coverage on VuMedi

A. Jain

12 views
21:44

ASH 2021 Updates on Efficacy and AE Management of BTKi in CLL/SLL

ASH 2021 Conference Coverage on VuMedi

J. Rhodes

252 views
11:34

ASH 2021 Updates on Novel Advances in AML Therapy

ASH 2021 Conference Coverage on VuMedi

E. Wang

227 views
17:05

ASH 2021 Updates on Therapy of p53 Mutant Hematologic Malignancies

ASH 2021 Conference Coverage on VuMedi

M. Davids

224 views
07:41

ASH 2021 Update on BOVen in CLL: Early MRD Kinetics Define a High-Ri…

ASH 2021 Conference Coverage on VuMedi

J. Soumerai

34 views
24:40

ASH 2021 Update on MRD in ALL: Standard of Care & Areas for Further …

ASH 2021 Conference Coverage on VuMedi

L. Muffly

454 views
10:28

ASH 2021 MRD Directed Therapy: A New Frontier in AML

ASH 2021 Conference Coverage on VuMedi

A. Wei

445 views